Welcome to Dividend.com
Please help us personalize your experience.
Select the one that best describes you
Johnson & Johnson logo

News

Cardinal Health To Acquire Johnson & Johnson's Cordis Business (CAH, JNJ)

Shauna O'Brien Mar 02, 2015

Before Monday’s opening bell, Cardinal Health (CAH ) announced that it has agreed to buy Johnson & Johnson’s (JNJ ) Cordis interventional medical devices business for $1.944 billion.

Cardinal Health will purchase the Cordis business from JNJ for $1.944 billion is cash. This transaction holds a value of approximately $1.594 billion with its tax benefits. Cardinal Health expects this transaction to benefit its FY2017 Non-GAAP EPS.

The deal is expected to be completed towards the end of 2015.

CAH’s CEO George Barrett commented:“The acquisition of Cordis is a significant step forward in our cardiovascular strategy. This acquisition follows a sequence of strategic moves for Cardinal Health in the areas of cardiology, wound management and orthopedics.”

Shares of JNJ were up 39 cents, or 0.38% during premarket trading Monday. The stock is down 1.97% YTD.

Shares of CAH were down 49 cents, or 0.56% during premarket trading Monday. The stock is up 8.99% YTD.

The Bottom Line

Cardinal Health (CAH ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Johnson & Johnson (JNJ ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Popular Articles